Dr. Anita Agarwal, MD

Dr. Agarwal practices at West Coast Retina in San Francisco, California.

Dr. Agarwal's NPI, 1508940628, was assigned on October 25, 2006. Dr. Agarwal graduated from Kasturba Medical College Manipal in 1986. Dr. Agarwal holds California license C143101.

Dr. Agarwal's primary practice is West Coast Retina, at 1445 Bush St, San Francisco, CA 94109-5520. The practice phone is (415) 972-4600.

Dr. Agarwal's primary practice is West Coast Retina in San Francisco, California. Dr. Agarwal is also affiliated with UCSF Health Stanyan Hospital. Dmand AI also links Dr. Agarwal to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Agarwal practices, 2 sites in all. Vendor and product names are available with a free account.

Retina specialist is Dr. Agarwal's primary specialty in the NPI Registry, under taxonomy code 207WX0107X. Dr. Agarwal is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Agarwal's licenses on file in 2 states: California and Tennessee.

Dmand AI lists age-related macular degeneration, cataract, cataract surgery with lens implant, conjunctivitis, dry eye, eyelid inflammation, glaucoma and hereditary corneal conditions among the conditions Dr. Agarwal treats.

CMS data shows 24,757 Medicare services from Dr. Agarwal across 13 procedure codes in 2024, for 973 Medicare patients. Medicare paid $2,341,025 for them. Every service was in an office.

CMS counts 973 Medicare patients who saw Dr. Agarwal in 2024. The largest group is 75 to 84, with 394 patients. 75% of them have high cholesterol, and 71% have high blood pressure. 17% are also on Medicaid. Their average risk score is 1.27, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Agarwal's median patient age at 72, with 51% women.

In 2024, Dr. Agarwal wrote 235 Medicare Part D claims for 89 patients. 54% of them were for generic drugs. CMS names the drug for 135 of them, across 3 drugs with 11 or more claims each, at $5,613 in total drug cost. In 2023, CMS named 202 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Agarwal for performance year 2024, reported as part of a group. Dr. Agarwal accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Cataract surgery: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 71 papers to Dr. Agarwal, published from 2000 to 2025. 2020 was the busiest year, with 4. The most frequent topics are Macular Degeneration, Polymorphism, Single Nucleotide and Fluorescein Angiography. Dr. Agarwal has published most often in Retin Cases Brief Rep. Dr. Agarwal's most frequent co-authors are Jaclyn Kovach, MD, Stephen G. Schwartz, MD and Caleb Chin Tao Ng.

Dmand AI links Dr. Agarwal to 1 clinical trial. Conditions studied include vitreous floaters and Epiretinal Membrane.

CMS Open Payments shows 14 general payments to Dr. Agarwal from 7 drug and device companies from 2016 to 2023. Food and beverage make up the largest share, 100% of the total. Genentech, Inc. paid the most, $106.

Dmand AI lists 9 awards for Dr. Agarwal, most recently Distinguished Contributor Award in 2024.

Dr. Agarwal graduated from Kasturba Medical College Manipal in 1986. Dr. Agarwal is a member of AAO.

Dr. Agarwal is in network with 15 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. Medicare plans come from the most carriers, 11. Check the plan with the practice before a visit.